In today’s recent session, 2.36 million shares of the Actinium Pharmaceuticals Inc (AMEX:ATNM) have been traded, and its beta is -0.17. Most recently the company’s share price was $1.94, and it changed around $0.45 or 30.19% from the last close, which brings the market valuation of the company to $60.51M. ATNM at last check was trading at a discount to its 52-week high of $10.24, offering almost -427.84% off that amount. The share price’s 52-week low was $1.03, which indicates that the recent value has risen by an impressive 46.91% since then. We note from Actinium Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.41 million shares, with the 3-month average coming to 239.73K.
Actinium Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ATNM as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Actinium Pharmaceuticals Inc is expected to report earnings per share of -0.39 for the current quarter.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
Instantly ATNM has been showing a green trend so far today with a performance of 30.19% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.1600 on recent trading dayincreased the stock’s daily price by 10.19%. The company’s shares are currently up 53.96% year-to-date, but still up 63.02% over the last five days. On the other hand, Actinium Pharmaceuticals Inc (AMEX:ATNM) is 65.80% up in the 30-day period. We can see from the shorts that 2.25 million shares have been sold at a short interest cover period of 13.64 day(s).
The consensus price target as assigned by Wall Street analysts is $4.95, which translates to bulls needing to increase their stock price by 60.81% from its current value. Analyst projections state that ATNM is forecast to be at a low of $4 and a high of $24.26.
Actinium Pharmaceuticals Inc (ATNM) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.80%. Actinium Pharmaceuticals Inc earnings are expected to increase by 34.00% in 2025, but the outlook is positive 13.33% per year for the next five years.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.79% of Actinium Pharmaceuticals Inc shares, and 29.67% of them are in the hands of institutional investors. The stock currently has a share float of 30.21%. Actinium Pharmaceuticals Inc stock is held by 102.0 institutions, with MARSHALL WACE, LLP being the largest institutional investor. By 2024-06-30, it held 0.8505% of the shares, which is about 0.26 million shares worth $1.89 million.
SCHONFELD STRATEGIC ADVISORS LLC, with 0.4711% or 0.14 million shares worth $1.05 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 938.63 shares worth $1.92 million, making up 3.01% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 816.68 shares worth around $1.67 million, which represents about 2.62% of the total shares outstanding.
